Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelica Petrillo

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Journal of Gastrointestinal Oncology|April 30, 2019
Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patientsAngelica Petrillo, Maria Maddalena Laterza, Giuseppe Tirino, et al.
Cancers|July 2, 2021
Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter StudyNicolas Williet, Angelica Petrillo, Gaël Roth, et al.
Future Oncology (London, England)|July 4, 2018
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapyAngelica Petrillo, Maria Maddalena Laterza, Giuseppe Tirino, et al.
International Journal of Molecular Sciences|January 8, 2023
Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter ExperienceMassimiliano Salati, Michele Ghidini, Matteo Paccagnella, et al.
Therapeutic Advances in Medical Oncology|January 27, 2025
Rare epithelial gastric cancers: a review of the current treatment knowledgeAngelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
Journal of Clinical Medicine|May 15, 2019
TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant AssociationPietro Zoppoli, Giovanni Calice, Simona Laurino, et al.
Medical Oncology (Northwood, London, England)|August 25, 2019
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatmentAngelica Petrillo, Annalisa Pappalardo, Luca Pompella, et al.
Cancer Treatment Reviews|February 11, 2025
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task forceChristelle de la Fouchardière, Antonella Cammarota, Magali Svrcek, et al.
BMC Cancer|September 4, 2016
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practiceFerdinando De Vita, Jole Ventriglia, Antonio Febbraro, et al.
Journal of Clinical Medicine|April 30, 2021
Bone Metastases from Gastric Cancer: What We Know and How to Deal with ThemAngelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Journal of Gastrointestinal Oncology|April 30, 2019
Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patientsAngelica Petrillo, Maria Maddalena Laterza, Giuseppe Tirino, et al.
Cancers|July 2, 2021
Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter StudyNicolas Williet, Angelica Petrillo, Gaël Roth, et al.
Future Oncology (London, England)|July 4, 2018
Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapyAngelica Petrillo, Maria Maddalena Laterza, Giuseppe Tirino, et al.
International Journal of Molecular Sciences|January 8, 2023
Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter ExperienceMassimiliano Salati, Michele Ghidini, Matteo Paccagnella, et al.
Therapeutic Advances in Medical Oncology|January 27, 2025
Rare epithelial gastric cancers: a review of the current treatment knowledgeAngelica Petrillo, Margaret Ottaviano, Luca Pompella, et al.
Journal of Clinical Medicine|May 15, 2019
TRPV2 Calcium Channel Gene Expression and Outcomes in Gastric Cancer Patients: A Clinically Relevant AssociationPietro Zoppoli, Giovanni Calice, Simona Laurino, et al.
Medical Oncology (Northwood, London, England)|August 25, 2019
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatmentAngelica Petrillo, Annalisa Pappalardo, Luca Pompella, et al.
Cancer Treatment Reviews|February 11, 2025
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task forceChristelle de la Fouchardière, Antonella Cammarota, Magali Svrcek, et al.
BMC Cancer|September 4, 2016
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practiceFerdinando De Vita, Jole Ventriglia, Antonio Febbraro, et al.
Journal of Clinical Medicine|April 30, 2021
Bone Metastases from Gastric Cancer: What We Know and How to Deal with ThemAngelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, et al.
Pageof 7